Kuwata Shingo, Vierecke Juliane, Gloekler Steffen, Maisano Francesco, Meier Bernhard, Nietlispach Fabian
University Heart Center Zurich.
Cardiol J. 2018;25(2):179-187. doi: 10.5603/CJ.a2017.0097. Epub 2017 Aug 25.
Percutaneous atrial septal defect (ASD) closure is a routine procedure to prevent right ventricular failure, pulmonary hypertension, or paradoxical embolism. The latter is the typical reason for percutaneous patent foramen ovale (PFO) closure. Atrial enlargement represents a risk for develop-ing atrial fibrillation (AF). Percutaneous left atrial appendage (LAA) closure is emerging as a preven-tive therapy for patients in AF who suffered from a previous stroke or bleeding (secondary prevention) or patients without previous stroke or bleeding (primary prevention). Percutaneous septal closure, particularly that of large ASDs, may inhibit future percutaneous left atrial access when required for LAA closure. Reported herein is the feasibility and safety of concomitant percutaneous closure of the LAA and a septal shunt, mostly large ASDs, in patients without AF, in the sense of "primary primary" preventive LAA closure. The first "primary" relates to "in anticipation of AF" and potentially also for "for prevention of AF". The second "primary" relates to "prevention of stroke or bleeding".
Thirteen consecutive patients, older than 40 years without any clinical or electrocardio-graphic evidence of AF, underwent percutaneous closure of large ASDs or PFOs in the presence of enlarged atria at the university hospitals of Bern and Zurich between April 2013 and June 2015. They concomitantly received "primary primary" preventive LAA closure after informed consent.
Mean patient age was 58 ± 9 years (46% male). Procedural success was achieved in all pa-tients and no major adverse events occurred acutely or during the following 2.0 ± 0.8 years. No patient developed AF.
Concomitant closure of ASD or PFO in the presence of enlarged atria and LAA for "primary primary" prevention appears feasible and safe but has yet to prove its justification.
经皮房间隔缺损(ASD)封堵术是预防右心室衰竭、肺动脉高压或反常栓塞的常规手术。后者是经皮卵圆孔未闭(PFO)封堵术的典型原因。心房增大是发生心房颤动(AF)的一个危险因素。经皮左心耳(LAA)封堵术正逐渐成为针对既往有中风或出血史的房颤患者(二级预防)或无既往中风或出血史的患者(一级预防)的一种预防性治疗方法。经皮间隔封堵术,尤其是大型ASD的封堵术,在需要进行LAA封堵时可能会限制未来经皮进入左心房。本文报道了在无房颤患者中,进行“一级一级”预防性LAA封堵时,同时经皮封堵LAA和间隔分流(主要是大型ASD)的可行性和安全性。第一个“一级”涉及“预期发生房颤”,可能也用于“预防房颤”。第二个“一级”涉及“预防中风或出血”。
2013年4月至2015年6月期间,在伯尔尼和苏黎世大学医院,13例年龄超过40岁、无任何临床或心电图证据表明患有房颤的患者,在心房增大的情况下接受了大型ASD或PFO的经皮封堵术。在获得知情同意后,他们同时接受了“一级一级”预防性LAA封堵术。
患者平均年龄为58±9岁(46%为男性)。所有患者手术均成功,术后2.0±0.8年期间未发生急性或重大不良事件。无患者发生房颤。
在心房增大的情况下同时封堵ASD或PFO并进行LAA“一级一级”预防似乎是可行和安全的,但尚未证明其合理性。